A Sticky Situation: Case Series of Successful Treatment of Glue Ear With Dupilumab.

IF 1.9 3区医学 Q3 CLINICAL NEUROLOGY

Otology & Neurotology Pub Date : 2025-05-07 DOI:10.1097/MAO.0000000000004501

Ethan M Kallenberger, Snimarjot Kaur, Brynn E Everist, Gregory A Ator, Selina A Gierer, Andrea F D'Mello

{"title":"A Sticky Situation: Case Series of Successful Treatment of Glue Ear With Dupilumab.","authors":"Ethan M Kallenberger, Snimarjot Kaur, Brynn E Everist, Gregory A Ator, Selina A Gierer, Andrea F D'Mello","doi":"10.1097/MAO.0000000000004501","DOIUrl":null,"url":null,"abstract":"Objective: To highlight the efficacy of dupilumab in treating chronic otitis media with effusion (glue ear).Patients: Three patients with chronic otitis media with effusion (OME) refractory to medical and surgical treatment were retrospectively identified. All patients had medical history suggestive of the presence of eosinophilic inflammation.Interventions: Each patient received a 300-mg injection of dupilumab every 4 weeks for a total of three injections.Main outcome measures: Audiometric data, patient-reported incidence of new ear infections, patient-reported symptoms.Results: All patients reported subjective improvement in ear pain, drainage, and hearing loss between 2 weeks and 6 months on dupilumab therapy. In case 1 and case 2, audiograms showed some improvement in hearing loss posttreatment. Case 2 had an unexpected interruption of treatment for 4 weeks and reported return of thick ear drainage and difficulty with hearing.Conclusions: Dupilumab may be a novel, effective, and nonsurgical treatment option for patients with chronic otitis media with effusion and underlying atopic conditions.","PeriodicalId":19732,"journal":{"name":"Otology & Neurotology","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Otology & Neurotology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MAO.0000000000004501","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To highlight the efficacy of dupilumab in treating chronic otitis media with effusion (glue ear).

Patients: Three patients with chronic otitis media with effusion (OME) refractory to medical and surgical treatment were retrospectively identified. All patients had medical history suggestive of the presence of eosinophilic inflammation.

Interventions: Each patient received a 300-mg injection of dupilumab every 4 weeks for a total of three injections.

Main outcome measures: Audiometric data, patient-reported incidence of new ear infections, patient-reported symptoms.

Results: All patients reported subjective improvement in ear pain, drainage, and hearing loss between 2 weeks and 6 months on dupilumab therapy. In case 1 and case 2, audiograms showed some improvement in hearing loss posttreatment. Case 2 had an unexpected interruption of treatment for 4 weeks and reported return of thick ear drainage and difficulty with hearing.

Conclusions: Dupilumab may be a novel, effective, and nonsurgical treatment option for patients with chronic otitis media with effusion and underlying atopic conditions.

查看原文本刊更多论文

粘稠的情况：杜比单抗成功治疗胶耳的案例系列。

目的：观察杜匹单抗治疗积液性慢性中耳炎（胶耳）的疗效。患者：回顾性分析了3例药物和手术治疗难治性慢性中耳炎积液（OME）患者。所有患者均有提示嗜酸性粒细胞炎症的病史。干预措施：每位患者每4周接受300 mg dupilumab注射，共注射3次。主要结局指标：听力数据、患者报告的新耳部感染发生率、患者报告的症状。结果：在dupilumab治疗的2周到6个月期间，所有患者都报告了耳痛、引流和听力损失的主观改善。病例1和病例2的听力图显示治疗后听力损失有所改善。病例2意外中断治疗4周，并报告耳部渗液变厚和听力困难。结论：Dupilumab可能是一种新的、有效的、非手术治疗慢性中耳炎积液和潜在的特应性疾病的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Otology & Neurotology 医学-耳鼻喉科学

CiteScore

3.80

自引率

14.30%

发文量

509

审稿时长

3-6 weeks

期刊介绍： Otology & Neurotology publishes original articles relating to both clinical and basic science aspects of otology, neurotology, and cranial base surgery. As the foremost journal in its field, it has become the favored place for publishing the best of new science relating to the human ear and its diseases. The broadly international character of its contributing authors, editorial board, and readership provides the Journal its decidedly global perspective.